Skip to main navigation
Invivyd
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Press Releases

Dec 19, 2022
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
Dec 06, 2022
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
Nov 17, 2022
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
Nov 10, 2022
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
Nov 09, 2022
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Nov 02, 2022
Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights
Oct 24, 2022
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
Oct 13, 2022
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
Oct 12, 2022
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
Sep 12, 2022
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 24
Invivyd

For general inquiries:
info@invivyd.com

For medical information
inquiries:
medinfo@invivyd.com

781-819-0080

  • Follow
  • Follow

1601 Trapelo Rd.
Suite 178
Waltham, MA 02451

Privacy Policy   |   Terms of Use   |   Cookie Policy